Merck & Company Inc (MRK)vsNexalin Technology Inc. (NXL)
MRK
Merck & Company Inc
$144.52
-2.23%
HEALTHCARE · Cap: $362.27B
NXL
Nexalin Technology Inc.
$1.56
+5.41%
HEALTHCARE · Cap: $1.54M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 31026793% more annual revenue ($67.38B vs $217,160). MRK leads profitability with a 3.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 42/100 (D).
MRK
Hold42
out of 100
Grade: D
NXL
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.0%
Fair Value
$84.93
Current Price
$144.52
$59.59 premium
Intrinsic value data unavailable for NXL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 35.2%
Generating 5.5B in free cash flow
Reasonable price relative to book value
Areas to Watch
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -319.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : NXL
The strongest argument for NXL centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : NXL
The primary concerns for NXL are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 4.66 is elevated, increasing financial risk.
Key Dynamics to Monitor
NXL carries more volatility with a beta of 4.34 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (42/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Nexalin Technology Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Nexalin Technology Inc. is a pioneering medical technology firm dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. By offering non-invasive solutions for prevalent mental health issues such as anxiety, depression, and substance addiction, the company underscores its commitment to improving patient outcomes and advancing accessible mental health care. With a robust research background and a strategic focus on tapping into the rising demand for innovative healthcare solutions, Nexalin is well-positioned for growth in the rapidly expanding digital health sector, presenting a compelling investment opportunity for institutional investors.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?